biomarin

Duchenne Muscular Dystrophy market to shoot up 100-fold in five years

As a whole host of new Duchenne Muscular Dystrophy therapies mature down the regulatory pathway, the global market for the degenerative disease is expected to expand at an incredible rate – from $8.2 million in 2014 to $990 million in 2019, or so says market research firm GlobalData. The present market’s got only paltry offerings to treat this […]

What’s the next big biopharma deal? Here are four contenders…

Life sciences M&A activity – and buzz – has hit a fever pitch in the past few months. As the industry braces itself for biosimilars to hit it big and precision medicine to drive development in targeted therapy, even more acquisitions are on the horizon. BioPharma Dive has compiled a tantalizing list of some potential acquisitions: […]